Nova’s non small cell lung cancer (NSCLC) disease model of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LUAD) includes intracellular signaling pathways, tumor cell dynamics with the immune system and tumor (including metastases) evolution. It allows investigating new treatments against EGFR mutant LUAD.
Model description (NSCLC)
Drugs that can be tested
Populations of interest
Possible clinical endpoints
Early insights to optimize your trial design
Combination of treatments
Get your questions answered by downloading the free pdf and learn more about your therapeutic area of interest!